Technical Intelligence & Insights
Dive into our comprehensive technical reports covering the Pharma Healthcare sector. We analyze novel patents, catalytic processes, and cost-reduction strategies to streamline your commercial manufacturing.
Patent CN108997229A reveals mild synthesis for high-purity intermediates. Enables cost reduction and scalable supply chain for global pharmaceutical manufacturing partners.
Patent CN115215809B reveals a high-yield route for oxazepam intermediates, offering cost reduction and supply chain reliability for pharmaceutical manufacturers.
Patent CN106432388B details a 4-step synthesis for Sofosbuvir intermediates. This report analyzes cost reduction and supply chain reliability for pharmaceutical manufacturing.
Patent CN103492351B details efficient dehydrogenation oxidation for carbonyl compounds. Enables cost reduction in fine chemical manufacturing and reliable supply chain.
Patent CN113045446A details a safe, acidic synthesis for Glupa-C, eliminating explosion risks and toxic amines for reliable diagnostic reagent supply chains.
Novel patent CN119735538B details high-purity Brivaracetam production. This route offers significant cost reduction and supply chain reliability for global pharmaceutical intermediate manufacturers.
Novel chemo-enzymatic route for pseudouridine offers high purity and scalable production for mRNA vaccine manufacturers seeking reliable supply.
Novel zinc-mediated reduction route for Roxadustat intermediates. High purity, scalable, and cost-effective manufacturing solution for pharmaceutical supply chains.
Patent CN104193645A reveals efficient asymmetric synthesis. Delivers >99.5% ee. Ideal for Cilastatin production. Cost-effective supply chain solution for global buyers.
Patent CN115109759A reveals engineered carbonyl reductases achieving 600g/g S/C ratio. Discover cost-effective biocatalytic routes for chiral alcohol production.
Patent CN108997355A reveals advanced recrystallization for Tofacitinib Citrate ensuring superior purity and yield for reliable pharmaceutical intermediates supplier partnerships.
Patent CN103159641A reveals low-cost lithiation route for tolvaptan intermediate ensuring high purity and supply chain stability for global pharmaceutical manufacturing.
Patent CN114196715A details a novel chemo-enzymatic method for pseudouridine using engineered glycosidase mutants, offering high conversion and simplified purification for mRNA vaccine supply chains.
Patent CN118374468B reveals mutant transaminase for high yield chiral amine intermediate production with improved stereoselectivity.
Patent CN105002234B reveals enzymatic cAMP synthesis. Offers high purity, cost reduction, and scalable supply for pharmaceutical intermediates manufacturing.
Patent CN106191150A details a co-immobilized enzymatic method for D-alanine. Achieves >98% purity with continuous 55-day operation, offering significant supply chain stability and cost reduction.
Novel Ni-catalyzed photochemical synthesis offers cost reduction and high enantioselectivity for pharmaceutical intermediates manufacturing.
Patent CN109943542A reveals enhanced ADH for Atazanavir. Lower cost, green synthesis, high purity pharmaceutical intermediates for global supply chains.
Enzymatic resolution patent CN112442523B enables high-purity chiral intermediate production with reduced costs and scalable supply chain reliability for global pharma.
Patent CN109576234B reveals a highly active V77A mutant enzyme enabling efficient biosynthesis of hydroxylated amino acids, offering significant cost reduction in API manufacturing and reliable supply chain solutions.